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ABSTRACT 
There is increasing interest in the role played by the cysteinyl 
leukotrienes in the pathogenesis of bronchial asthma. They 
have been demonstrated to have a bronchoconstrictor effect 
both in vitro and in vivo and have been isolated from bron-
choalveolar lavage fluid and urine from stable asthmatics 
and from asthmatics during exacerbations and after endo-
bronchial challenge. Pharmacological intervention has been 
studied through antagonism of leukotriene receptors and 
inhibition of leukotriene synthesis. Both have been shown to 
have an effect on the asthmatic response after challenge with 
allergen, exercise and inhalation of cold air and to have an 
effect on aspirin sensitive asthmatics and on the symptoms 
and markers of severity of chronic asthma. The differences 
between receptor antagonism and synthesis inhibition are 
discussed.
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INTRODUCTION 
There is increasing evidence for the role played by the cysteinyl 
leukotrienes LTC4, LTD4 and LTE4 in the pathogenesis of 
bronchial asthma. Evidence is also accumulating that pharma-
cological manipulation through antagonism or inhibition of 
their synthesis might be clinically useful in the treatment of 
asthma. 
 The cysteinyl leukotrienes are generated by the enzyme 5-
lipoxygenase (5LO; Fig. 1) which acts on arachidonic acid in 
conjunction with 5LO associated protein (FLAP) to generate the 
unstable epoxide LTA4. This is then either converted to LTB4 or,
via LTC4 synthase, to the cysteinyl leukotriene LTC4 which is sub-
sequently converted by y-glutamyltranspeptidase to LTD4 and by 
a dipeptidase to LTE4.
BRONCHOCONSTRICTOR EFFECT OF THE 
LEUKOTRIENES
In vitro studies with LTC4 have demonstrated a contractile action 
on isolated human bronchus2 and tracheal smooth muscle3 with 
a potency of 1000 times that of histamine. Isolated human 
bronchi of diameter 3-12mm have a high degree of baseline 
bronchomotor tone equivalent to 50% of maximal broncho-
constriction induced by. BaCI2. This resting tone is reduced by 
preincubation with the LTD4 antagonists ICI 204,219 and SKF 
104,353 and this reduction is additive to that induced by the 
addition of histamine Hl antagonists suggesting thatthis resting 
tone is mediated by the continuous production of histamine and 
leukotrienes.4
In vivo studies have revealed a bronchoconstrictor effect of 
inhaled nebulized solutions of leukotrienes in both normal and 
asthmatic individuals. In normal subjects, LTC4 is 600-9500 
times as potent as histamine in causing a 30% fall in expiratory 
flow at a lung volume of 30% of baseline vital capacity above 
residual volume.5 LTD4 was found to be 6000 times more potent 
than histamine.b LTE4 appears to be only 40-60 times as potent 
as histamine but has a longer duration of action when com-
pared to the other cysteinyl leukotrienes.7,8 
In asthmatic individuals the leukotrienes also have a bron-
choconstrictor effect. However, in asthmatics LTC4 is only 40 
times as potent as histamine in inducing bronchoconstriction9 
and LTD4 only 140 times as potent.10 Further studies have 
confirmed that the relative (to histamine) potencies of LTC4 and 
LTD4 are reduced in asthmatics when compared to non-
asthmatics.11
 A further study has shown that when compared to normal 
individuals, asthmatics have a 14-fold greater response to his-
tamine, a 15-fold greater response to methacholine, a 6-fold 
greater response to LTC4, a 9-fold greater response to LTD4, and 
a 219 times greater response to LTE4. Furthermore, as airways
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became more hyperresponsive as judged by their response to 
histamine and methacholine, so the relative potency of LTE4 
increases when compared to LTC4 and LTD4.12
Aspirin-sensitive asthma 
Studies in asthmatics whose asthma is precipitated by aspirin 
have shown that these individuals are exquisitely sensitive to 
LTE4. In aspirin-sensitive asthmatics LTE4 is 1870 times more 
potent than histamine in inducing bronchospasm whereas in 
non-aspirin-sensitive asthmatics, LTE4 is only 145 times as 
potent as histamine.13 Furthermore, desensitization of these 
patients to aspirin leads to a fall in the relative potency of LTE4 
by 20-fold, suggesting that LTE4 plays a part in the induction of 
bronchospasm in this group. This hyperresponsiveness is spe-
cific to LTE4 and is not seen with LTC4.14
 These studies suggest that LTC4 and LTD4 appear to have less 
relative potency in asthmatics when compared to normal indi-
viduals but that asthmatic airways, and especially those of 
aspirin-sensitive asthmatics, have a disproportionate respon-
siveness to LTE4. This implies that LTE4 may play an important 
role in bronchial asthma, perhaps because of its stability and 
the fact that it persists for the longest time at its site of release.15
ISOLATION OF LEUKOTRIENES FROM ASTHMATICS 
Various investigators have looked at the concentrations of 
leukotrienes in the bronchoalveolar lavage fluid (BALF) and 
urine of asthmatics. A study of 17 subjects with mild to severe 
asthma revealed that 15 had detectable levels of LTE4 in BALF 
whereas no LTE4 was detected in nine controls.14 Similarly, 
Wardlaw et al. found increased levels of LTB4 and LTC4 in the 
BALF of eight symptomatic asthmatics when compared to 14 
controls.16 Drazen et al. looked at 72 patients attending acci-
dent and emergency departments with asthma and found that 
urinary LTE4 levels were higher in those who responded to a 
nebulized bronchodilator when compared to those who did not, 
suggesting that cysteinyl leukotrienes may have a broncho-
spastic role in acute asthma.17
ENDOBRONCHIAL CHALLENGE 
Wenzel et al. investigated a group of atopic asthmatics with 
endobronchial allergen challenge and found that LTC4 was the 
predominant leukotriene and increased 9-fold after chal-
lenge.18 In addition, whereas LTC4 was detected in 9 of 11 
atopic asthmatics at baseline, it was detected in only one out of 
seven atopic non-asthmatics and one out of six non-atopics. A 
further study by the same group19 measured levels of the mast 
cell derived products PGD2, TXB2, LTC4 and histamine before 
and 5 min after endobronchial allergen challenge in seven non-
asthmatics, six asthmatics and six asthmatics with a late asth-
matic response (LAR), all of whom were atopic.19 Detectable 
levels of LTC4 were found in 9 out of 12 of the asthmatics and in
ly one out of seven of the non-asthmatics. An increase in all 
f ur mediators after challenge was found in the asthmatics only. 
In addition, the asthmatic group without a LAR had a greater 
increase in mediator levels when compared with asthmatics with 
a LAR. In a study of allergen provocation sufficient to cause 
25-59% fall in FEV, (forced expiratory volume in one second) in 
17 allergic asthmatics, urinary LTE4 levels were found to 
increase from 46 to 92ng/24h. No increase in urinary LTE4 was 
detected after methacholine challenge caused a similar fall in 
FEV,. Whereas a correlation existed between urinary LTE4 and 
the decrease in FEY, in the early asthmatic response (EAR), there 
was no correlation with the fall in FEV1, in the LAR.20 
 Manning et al. looked at 18 asthmatics and found an 
increase in urinary LTE4 in those with an early asthmatic 
response and that the degree of bronchoconstriction correlated 
with the level of urinary LTE4.21 Those with a dual asthmatic 
response had a lesser but still significant increase in urinary LTE4 
and those with an isolated LAR had no increase. Cysteinyl 
leukotrienes, therefore, appear to be important in the EAR and 
contribute significantly to the degree of bronchoconstriction.
Aspirin-sensitive asthma 
Christie et al. have demonstrated a 6-fold increase in urinary 
LTE4 in aspirin-sensitive asthmatics when compared to normal 
individuals and non-aspirin-sensitive asthmatics.22 Six aspirin-
sensitive asthmatics had a 4-fold increase in urinary LTE4 after 
oral aspirin challenge which led to a 21% fall in FEV1, whereas 
a control group had no fall in FEV1 and no increase in urinary 
LTE4 levels after aspirin ingestion.
LEUKOTRIENE ANTAGONISTS 
The evidence for the role of the cysteinyl leukotrienes in asthma 
has been supported by studies involving both leukotriene antag-
onists and agents which inhibit their synthesis. Several studies 
suggest that a number of LTD4 antagonists developed for use in 
human trials have a blunting effect on the fall in FEV1 seen in 
asthmatics when experimentally challenged with allergen, exer-
cise, inhalation of cold dry air and aspirin. 
 The first generation antagonists LY 171,883 and LY 649,923 
produce a slight fall in the EAR after allergen challenge but have 
no effect on baseline FEV, or the LAR.23,24 Ten asthmatics pre-
treated with the selective and potent second generation oral 
agent ICI 204,219 showed a reduction of 80% in their EAR and 
of 50% in their LAR (Fig. 2).25 Treatment also suppressed an 
i crease in bronchial reactivity 6h post challenge. Inhaled ICI 
204,219 was not as effective and although it reduced the EAR, 
it ad no effect on the LAR.26 In addition, a single dose of inhaled 
ICI 204,219 produced a 10-fold rightward shift in the dose 
r sponse curve to inhaled cat allergen.27 Inhaled ICI 204,219 
lso led to a shortening of the recovery time of the EAR from 60 
to 40 min.28 The quinolone derivative MK571 has also been 
hown to inhibit the EAR by 88% and the LAR by 63%.29
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 Studies in exercise-induced asthma have shown that SK & F 
104,353, a weak LTD4 antagonist, led to a reduction from 29 to 
20% in the exercise-induced bronchoconstrictor response, this 
being of a similar degree to that seen with sodium cromogly-
cate.30 In a model for exercise-induced asthma, oral treatment 
with ICI 204,219 resulted in a reduction in the fall in FEV1 after 
inhalation of cold dry air from 36 to 21% in eight asthmatics.33 
A further study on the same compound revealed a halving of the 
fall in FEV1 after exercise in nine asthmatics.32 MK571 also led 
to a decrease in the fall in FEV1 and a shortening in the recovery 
time from 33 to 8 min in 12 asthmatics after exercise (Fig. 3) 33 
However, despite their potency, LTD4 antagonists were unable to 
abolish the bronchospastic response to exercise completely, 
suggesting that other mediators such as mast cell histamine and 
prostaglandins are important in this reaction.
 Aspirin-sensitive asthma is probably the most leukotriene-
dependent model for the investigation of anti-leukotriene ther-
apy. The weak LTD4 antagonist SK & F 104,353 reduced the 
response to ingested aspirin by a mean of 47% in five out of six 
subjects.34 The quinolone derivative MK679 was found to 
improve baseline function in eight aspirin-sensitive asthmatics 
and to block the airways obstruction caused by inhaled lysine 
aspirin, producing a 4.4-fold rightward shift in the dose 
response curve.35
Fig. 1 Leukotriene biosynthesis. LT, leukotriene; 5-HETE, 5-hydroxy-
eicosatetraenoic acid; 5-H PETE, 5-hydroperoxyeicosatetraenoic.
Bronchodilator effect 
Several studies have shown that leukotriene antagonists have a 
bronchodilator effect on asthmatics. Intravenous treatment with 
MK679 led to an increase in baseline FEV1 of up to 15.8% in a 
group of nine asthmatics with resting FEV1 of between 40 and 
80% of that predicted by age and height.36 Oral administration 
of ICI 204,219 led to an increase in resting FEV1 compared to 
placebo with the effect of salbutamol being additive.37 This 
additive effect was confirmed in a study of 12 asthmatics treated 
with intravenous MK571, with the degree of bronchodilation
Fig.2 Effect of (○) ICI 204,219 and (●) placebo on early and late
responses to allergen challenge. Reproduced with permission from The
Lancet Ltd. (Ref. 25).
Fig. 3 Mean percentage change in FEV, after exercise following treat-
ment with
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being inversely proportional to the baseline FEV1 and additive to 
that produced by albuterol (Fig. 4).38 MK679 also led to an 
18% increase in FEV1 in eight aspirin-sensitive asthmatics with 
the degree of bronchodilation again strongly correlating with 
the severity of asthma39 suggesting that cysteinyl leukotrienes 
play a major role in determining resting tone. Treatment with 
MK476 led to a 12% increase in FEY, in a group of moderate 
asthmatics.40 Addition of the LTD4 antagonist RG 12525 to 
existing steroid treatment led to an increase in FEV1 in stable 
asthmatic subjects.41
Chronic asthma 
The LTD4 antagonists also appear to provide symptomatic ben-
efit in chronic asthma. Treatment with oral LY 171,883 for 6 
weeks in a group of 138 asthmatics led to an increase in FEV1 
from 73.8 to 83.3% of that predicted by age and height, an 
improvement in symptoms of wheeze and dyspnea and a
decrease in the use of β-2 agonists, but no change in cough or
chest tightness.42 Oral MK571 treatment for 6 weeks led to an 
8-14% increase in FEV, and a 30% reduction in salbutamol 
usage.43 Six weeks of oral ICI 204,219 in mild to moderate 
asthma led to an improvement in their daytime asthma score, 
nocturnal awakenings and morning peak flow recordings.39 A 
study of varying doses of the antagonist ICI 204,219 in 266 
moderate asthmatics found a reduction in nocturnal awakening 
(by 46%), a decrease in first morning asthma symptoms, day-
time asthma scores (by 26%) and salbutamol use (by 30%), and 
an increase in FEV1 (by 11%) and evening peak expiratory flow 
rates (PEFR).44
5-LIPOXYGENASE (5LO) INHIBITORS 
There are a number of theoretical arguments to suggest that 
an inhibition of 5LO would be more effective than antagonism of 
a specific leukotriene receptor. First, inhibition of 5LO leads to a 
reduction in not only the cysteinyl leukotrienes LTC4, LTD4 and 
LTE4, but also LTB4.45 In addition, there is evidence that leukotriene 
receptor antagonism alone may prolong the half lives of some of 
the leukotrienes by interfering with their elimination, thereby pos-
sibly potentiating their action.36 Studies on the 5LO inhibitors 
have addressed their effect on the asthmatic response to chal-
lenge with allergen, cold air, exercise and aspirin. 
 In a study of nine asthmatics, the 5LO inhibitor, zileuton, led 
to complete inhibition of ex vivo whole blood LTB4 generation 
and a reduction of 50% in the rise of urinary LTE4 post-allergen 
challenge. However, there was no reduction in the EAR or LAR 
and no reduction in airway responsiveness post-challenge.47 
The potent and selective inhibitor ZD2138 led to an 82% fall in 
ex vivo whole blood LTB4 generation and a 72% decrease in the 
rise in urinary LTE4 but again had no effect on the EAR or the 
LAR.48 A study of eight atopic men wtih the translocation
Fig. 4 Mean change in FEVJ in asthmatic patients with existing airways
obstruction after infusion of
Fig. 5 Mean percentage change in FEV1 after aspirin challenge after
premedication with the
inhibitor MK886 revealed a fall in the EAR of 58% and a fall in 
the LAR of 44%. This was accompanied by a 54% fall in the 
A23187 stimulated whole blood LTB4 generation and a 51.5% 
inhibition in the rise of urinary LTE4 in the EAR and an 80% inhi-
bition during the LAR.49 
 Administration of the FLAP inhibitor MK0591 prior to aller-
gen challenge led to a 96% inhibition of LTB4 and an 84% inhi-
bition of urinary LTE4 production 24 h post-allergen challenge. 
In addition, there was a fall of 79% in the EAR and the LAR was 
delayed by 3 h.50 BAYx1005, a FLAP inhibitor of similar potency 
to MK0591, was administered to atopic asthmatics and led to a 
reduction of 68% in the EAR to inhaled allergen and an 87% 
reduction in urinary LTE4.51
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 Thirteen asthmatics premedicated with a single dose of zileu-
ton had a reduction in ex vivo LTB4 generation of 74% and an 
increase of 47% in the amount of cold air required to cause a 
fall in FEV, of 10%.52 Twenty-four asthmatics treated wtih a 2 
day course of zileuton had a 40% fall in the amount of exercise 
induced bronchospasm.53 
 Treatment with zileuton in eight aspirin-sensitive asthmatics 
led to a fall in urinary LTE4 of 70% and prevented a drop in FEV1 
after aspirin challenge.54 Similarly, ZD2138 protects against 
aspirin-induced asthma with a 20.3% fall after challenge 
and treatment with placebo, and a fall of 4.9% after treatment 
with ZD2138 was associated with a reduction in whole blood 
LTB4 generation of 72% and of urinary LTE4 of 74% at 6 h 
(Fig. 5) 55
Chronic asthma
Studies have been conducted to assess the effect of the 5LO 
inhibitors on baseline FEV1 and symptoms in chronic asthma. 
Treatment with zileuton led to an increase in baseline FEV1 of 
15% after 1 h in a group of chronic asthmatics treated with 
salbutamol only.56 Treatment of a group of aspirin-sensitive 
asthmatics with ZD2138 led to a 10% increase in baseline 
FEV1.55 In a study of 139 asthmatics with a baseline FEV1 of 
between 40 and 75% of that predicted by age and height and 
not taking steroids, zileuton led to a 13.6% increase in FEV,, a
decrease in asthma symptom score, a decrease in β-2 agonist
use and a decrease in excreted urinary LTE4.56 In a group of 398 
asthmatics treated with salbutamol only and with a mean base-
line FEV1 of 61%, treatment with zileuton for 13 weeks led to an 
increase in FEV1 of 0.251 compared with 0.081 with placebo.56 
For 4 weeks, 109 asthmatics with baseline FEV1 ranging from 
50 to 75% of predicted were treated with inhaled steroids with 
MK0591 or placebo. The group treated with MK0591 had an 
increase in their FEV1 of 6.8% whereas placebo had an increase 
of 0.6%. Increases in morning and evening PEFR of 19 and 
135% respectively, were also noted as was a decrease in 13-2 
agonist use.57
CONCLUSION
It appears that despite theoretical advantages over the 
leukotriene antagonists the 5-lipoxygenase (5LO) antagonists 
do not suppress leukotriene mediated processes any more than 
the leukotriene antagonists. This may be because, although 
5LO inhibitors are effective in reducing ex vivo LTB4 generation 
and urinary LTE4 excretion, they are not potent enough to inhibit 
intra-airways Leukotriene generation and that even small 
amounts of leukotrienes in this area may be able to exert patho-
logical effects. In addition, 5LO inhibition may decrease the 
amount of lipoxin A4 generated which may itself have a moder-
ating effect on leukotriene action.' Similarly, inhibition of 5LO 
may lead to shunting of arachidonic acid derivatives down the
cyclooxygenase pathway with the generation of proinflamma-
tory products. 
 F rther details are needed to investigate whether these com-
pounds have steroid sparing effects and their effect on long-
t rm symptoms. Similarly, biopsy studies to investigate the 
effects on airways inflammation of these compounds are 
needed. Finally, although there is evidence that leukotrienes are 
implicated in the pathogenesis of asthma and that pharmaco-
lo ical modification of their action has been shown to be effec-
tiv  in both models of acute asthma and on chronic asthma, it 
should be noted that leukotrienes are just one of many proin-
flammatory compounds active in asthma.
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